Total Payments
$435,758
2024 Payments
$1,939
Companies
69
Transactions
1,831
Medicare Patients
5,542
Medicare Billing
$422,729
Payment Breakdown by Category
Other$336,004 (77.1%)
Travel$44,908 (10.3%)
Food & Beverage$28,784 (6.6%)
Consulting$23,025 (5.3%)
Research$2,323 (0.5%)
Education$654.89 (0.2%)
Gifts$59.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $336,004 | 277 | 77.1% |
| Travel and Lodging | $44,908 | 190 | 10.3% |
| Food and Beverage | $28,784 | 1,335 | 6.6% |
| Consulting Fee | $23,025 | 10 | 5.3% |
| Unspecified | $2,323 | 6 | 0.5% |
| Education | $654.89 | 12 | 0.2% |
| Gift | $59.40 | 1 | 0.0% |
Payments by Type
General
$433,435
1,825 transactions
Research
$2,323
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $231,074 | 555 | $0 (2024) |
| Novo Nordisk Inc | $43,052 | 108 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $42,214 | 125 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $35,748 | 104 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $34,324 | 116 | $0 (2024) |
| Merck Sharp & Dohme LLC | $21,911 | 82 | $0 (2023) |
| Mannkind Corporation | $5,662 | 158 | $0 (2024) |
| Eli Lilly and Company | $5,659 | 25 | $0 (2021) |
| ABBVIE INC. | $4,037 | 22 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,094 | 29 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,939 | 89 | Lilly USA, LLC ($190.42) |
| 2023 | $3,858 | 181 | MannKind Corporation ($629.48) |
| 2022 | $8,319 | 120 | Lilly USA, LLC ($6,760) |
| 2021 | $5,714 | 63 | Lilly USA, LLC ($4,588) |
| 2020 | $35,737 | 105 | Lilly USA, LLC ($23,557) |
| 2019 | $131,093 | 406 | Lilly USA, LLC ($88,801) |
| 2018 | $99,917 | 384 | Lilly USA, LLC ($22,429) |
| 2017 | $149,180 | 483 | Lilly USA, LLC ($84,307) |
All Payment Transactions
1,831 individual payment records from CMS Open Payments — Page 1 of 74
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $17.03 | General |
| Category: DIABETES MEDICINE | ||||||
| 12/06/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $16.44 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 12/05/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $23.20 | General |
| Category: Biological | ||||||
| 11/25/2024 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $13.32 | General |
| Category: Insulin Pump | ||||||
| 11/20/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $25.87 | General |
| Category: Diabetes | ||||||
| 11/19/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $24.27 | General |
| Category: Endocrinology | ||||||
| 11/07/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/05/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $29.13 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 11/04/2024 | Tandem Diabetes Care, Inc. | t:slim X2 Insulin Pump with Control-IQ (Device) | Food and Beverage | In-kind items and services | $32.71 | General |
| Category: Endocrinology | ||||||
| 10/29/2024 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $17.78 | General |
| Category: Endocrinology | ||||||
| 10/24/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $14.38 | General |
| Category: Endocrinology | ||||||
| 10/11/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $2.86 | General |
| Category: Diabetes | ||||||
| 10/10/2024 | Embecta Corp. | BD Nano 2nd Gen Pen Needle (Device) | Food and Beverage | In-kind items and services | $28.40 | General |
| Category: Diabetes Care | ||||||
| 10/07/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $23.34 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/01/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $28.48 | General |
| Category: DIABETES | ||||||
| 09/23/2024 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $18.76 | General |
| Category: Endocrinology | ||||||
| 09/16/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $14.69 | General |
| Category: Bone Health | ||||||
| 09/12/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $17.32 | General |
| Category: DIABETES MEDICINE | ||||||
| 09/11/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $22.98 | General |
| Category: Diabetes | ||||||
| 09/11/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $16.27 | General |
| Category: Automated insulin delivery system | ||||||
| 09/10/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $13.30 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 09/09/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $21.79 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/05/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $6.55 | General |
| Category: Diabetes | ||||||
| 09/04/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $22.66 | General |
| Category: Obesity | ||||||
| 09/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.23 | General |
| Category: Cardio-renal | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN STUDY PARTICIPANTS WITH TYPE 1 DIABETES MELLITUS PREVIOUSLY TREATED WITH MULTIPLE DAILY INJECTION THERAPY | Eli Lilly and Company | $1,613 | 2 |
| safety and efficacy linagliptin vs SU | Boehringer Ingelheim b.v. | $709.15 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 1,239 | 1,910 | $304,005 | $70,591 |
| 2022 | 23 | 1,131 | 1,889 | $400,090 | $100,231 |
| 2021 | 12 | 952 | 1,894 | $447,073 | $121,781 |
| 2020 | 29 | 2,220 | 3,326 | $578,598 | $130,126 |
Total Patients
5,542
Total Services
9,019
Medicare Billing
$422,729
Procedure Codes
87
All Medicare Procedures & Services
87 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 251 | 367 | $121,110 | $27,931 | 23.1% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 24 | 160 | $25,120 | $6,096 | 24.3% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 27 | 142 | $27,690 | $5,497 | 19.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 38 | 38 | $19,190 | $4,664 | 24.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 72 | 88 | $19,536 | $4,640 | 23.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 17 | 23 | $10,258 | $2,651 | 25.8% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 99 | 142 | $9,798 | $2,337 | 23.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $9,525 | $2,158 | 22.7% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 52 | 70 | $9,310 | $1,743 | 18.7% |
| 95250 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | Office | 2023 | 13 | 14 | $6,734 | $1,660 | 24.6% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 16 | 17 | $6,052 | $1,559 | 25.8% |
| 82306 | Vitamin d-3 level | Office | 2023 | 37 | 45 | $4,995 | $1,305 | 26.1% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 86 | 123 | $5,289 | $1,263 | 23.9% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2023 | 18 | 25 | $4,225 | $1,011 | 23.9% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 59 | 76 | $4,180 | $997.12 | 23.9% |
| 84439 | Thyroxine (thyroid chemical), free | Office | 2023 | 80 | 106 | $3,922 | $937.04 | 23.9% |
| 84481 | Thyroid hormone, t3 measurement, free | Office | 2023 | 39 | 56 | $3,864 | $929.60 | 24.1% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 66 | 89 | $3,560 | $847.28 | 23.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 65 | 90 | $2,880 | $684.90 | 23.8% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 14 | 33 | $2,013 | $585.90 | 29.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 41 | 49 | $494.00 | $411.60 | 83.3% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2023 | 91 | 112 | $1,120 | $359.52 | 32.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 19 | 30 | $3,140 | $321.77 | 10.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 349 | 806 | $265,980 | $68,185 | 25.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 90 | 130 | $28,860 | $7,516 | 26.0% |
About Dr. Rakesh Patel, DO
Dr. Rakesh Patel, DO is a Endocrinology, Diabetes & Metabolism healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/08/2005. The National Provider Identifier (NPI) number assigned to this provider is 1386629699.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rakesh Patel, DO has received a total of $435,758 in payments from pharmaceutical and medical device companies, with $1,939 received in 2024. These payments were reported across 1,831 transactions from 69 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($336,004).
As a Medicare-enrolled provider, Patel has provided services to 5,542 Medicare beneficiaries, totaling 9,019 services with total Medicare billing of $422,729. Data is available for 4 years (2020–2023), covering 87 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Houston, TX
- Active Since 12/08/2005
- Last Updated 09/14/2007
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1386629699
Products in Payments
- TRULICITY (Drug) $172,593
- JARDIANCE (Drug) $53,403
- BYDUREON (Drug) $22,439
- STEGLATRO (Drug) $21,334
- FARXIGA (Drug) $19,620
- Tresiba (Drug) $19,571
- SOLIQUA (Drug) $18,634
- TOUJEO (Drug) $11,182
- BASAGLAR (Drug) $10,826
- Victoza (Drug) $9,733
- AFREZZA (Drug) $5,662
- MOUNJARO (Drug) $3,778
- SOLIQUA 100/33 (Biological) $2,589
- Synthroid (Drug) $2,209
- Xultophy 100/3.6 (Drug) $1,919
- Androgel (Drug) $1,752
- SOLIQUA 100/33 (Drug) $1,294
- V-GO (Device) $1,087
- INVOKANA (Drug) $1,023
- TRADJENTA (Drug) $816.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Houston
Dr. Rocio Harbison, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $1.1M
Endocrinology, Diabetes & Metabolism $1.1M
Dr. Andres Splenser, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $998,793
Endocrinology, Diabetes & Metabolism $998,793
Damaris Vega, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $995,666
Endocrinology, Diabetes & Metabolism $995,666
Dr. Steven Petak, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $388,893
Endocrinology, Diabetes & Metabolism $388,893
Dr. Veena Watwe, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $224,669
Endocrinology, Diabetes & Metabolism $224,669
Dr. Brian Tulloch, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $174,403
Endocrinology, Diabetes & Metabolism $174,403